nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

23.08.2022 | Original Article

Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients

verfasst von: Caihua Zhu, Bing Dai, Hua Zhan, Ruoyu Deng

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Programmed cell death protein 1 (PD-1) inhibitor is widely utilized in advanced-stage carcinomas including hepatocellular carcinoma (HCC), while its neoadjuvant application plus transarterial chemoembolization (TACE) in HCC remains unexplored. Thereby, the current study aimed to investigate the efficacy and safety of TACE plus PD-1 inhibitor as neoadjuvant therapy bridging to surgical resection in intermediate-stage HCC patients.

Methods

Twenty intermediate-stage HCC (China Liver Cancer (CNLC) stage II) patients treated with neoadjuvant TACE plus PD-1 inhibitor (camrelizumab or sintilimab) bridging to surgery were consecutively enrolled.

Results

The objective response rate (ORR) and disease control rate (DCR) to neoadjuvant therapy were 75.0% and 100.0%, respectively; meanwhile, alpha-fetoprotein (AFP) was decreased after the neoadjuvant therapy (P < 0.001). Moreover, 14 (70.0%) patients had successful downstaging (patients converted to CNLC stage I). Neither median disease-free survival (DFS) nor median overall survival (OS) was reached; additionally, the 1-year accumulating DFS rate was 86.6%; meanwhile, the 1-year and 2-year accumulating OS rates were 100.0% and 76.4%, separately. Moreover, patients with successful downstaging had a prolonged DFS (P = 0.014) compared to patients with failed downstaging; meanwhile, this trend was also observed in assessing accumulating OS (P = 0.067) (without statistical significance). Main adverse events included pain (50.0%), fever (25.0%), neutropenia (25.0%), nausea and vomiting (25.0%), fatigue (25.0%), peripheral neuropathy (20.0%), anemia (15.0%), thrombopenia (15.0%), diarrhea (15.0%), anorexia (15.0%), and rash (15.0%).

Conclusion

Neoadjuvant TACE plus PD-1 inhibitor realizes a satisfying downstaging rate, acceptable survival profile, and tolerance in intermediate-stage HCC patients.

Flores YN, Datta GD, Yang L et al (2021) Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev 30(6):1193–1199CrossRefPubMedPubMedCentral

Konyn P, Ahmed A, Kim D (2021) Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 15(11):1295–1307CrossRefPubMed

Benson AB, D'Angelica MI, Abbott DE et al (2021) Hepatobiliary cancers, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(5):541–565

Reig M, Forner A, Avila MA et al (2021) Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 156(9):463 e461–463 e430

Zhou WP, Lai EC, Li AJ et al (2009) A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249(2):195–202CrossRefPubMed

Ho WJ, Zhu Q, Durham J et al (2021) Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer 2(9):891–903CrossRefPubMedPubMedCentral

Jaworska K, Ratajczak J, Huang L et al (2015) Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol 194(1):325–333CrossRefPubMed

Sangro B (2014) Chemoembolization and radioembolization. Best Pract Res Clin Gastroenterol 28(5):909–919CrossRefPubMed

Wang Q, Xie B, Liu S et al (2021) What happens to the immune microenvironment after PD-1 inhibitor therapy? Front Immunol 12:773168CrossRefPubMedPubMedCentral

10.

Xin H, Zhang C, Ding Z et al (2022) TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports. Clin Res Hepatol Gastroenterol 46(1):101777CrossRefPubMed

11.

Lu W, Jin XL, Yang C et al (2017) Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. Cancer Biol Ther 18(6):433–438CrossRefPubMedPubMedCentral

12.

Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A et al (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62(4):1111–1121CrossRefPubMed

13.

Cai L, Li H, Guo J et al (2021) Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin Res Hepatol Gastroenterol 45(4):101535CrossRefPubMed

14.

Li B, Qiu J, Zheng Y et al (2021) Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma

15.

Zhang W, Hu B, Han J et al (2020) Preliminary report on the study of conversion therapy of advanced hepatocellular carcinoma combined PD-1 inhibitors with multi-target tyrosine kinase inhibitors. J Chinese J Hepatob Surg 26:947–948

16.

Orcutt ST, Anaya DA (2018) Liver resection and surgical strategies for management of primary liver cancer. Cancer Control 25(1):1073274817744621CrossRefPubMedPubMedCentral

17.

Xie DY, Ren ZG, Zhou J et al (2020) 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 9(4):452–463CrossRefPubMedPubMedCentral

18.

Vogel A, Martinelli E, clinicalguidelines@esmo.org EGCEa, Committee EG (2021) Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 32(6):801–805

19.

Pinato DJ, Cortellini A, Sukumaran A et al (2021) PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer 21(1):301CrossRefPubMedPubMedCentral

20.

Sasaki A, Iwashita Y, Shibata K et al (2006) Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32(7):773–779CrossRefPubMed

Titel: Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
verfasst von: Caihua Zhu
Bing Dai
Hua Zhan
Ruoyu Deng
Publikationsdatum: 23.08.2022
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 3/2023
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-022-03131-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Evaluation of the efficiency and complications of the consecutive proning in COVID-19 ICU: a retrospective study

The price of private dental services: results from a national representative survey of Ireland

Black and non-black population: investigation of the difference in butyrylcholinesterase activity in a healthy population in Salvador, Bahia

Reason for peripheral blood natural killer cell depletion in severe COVID-19 patients

Barriers to attendance at a tertiary hospital’s perinatal mortality meeting

Fluid and electrolyte management: increasing the knowledge of House Officers using an interactive eLearning tool